Clinical Trials Directory

Trials / Completed

CompletedNCT03372239

Oral Bioavailability,and Food Effect Study and Single Ascending Dose PK Study in Healthy Male Volunteers

A Phase 1, Randomized Trial to Compare the Oral Bioavailability of Indoximod Salt and Base Formulations and the Effect of Food (Part 1) and to Evaluate the PK and Safety of Single Ascending Doses of Indoximod (Part 2) in Healthy Male Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
48 (actual)
Sponsor
NewLink Genetics Corporation · Industry
Sex
Male
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

This 2-part study will assess the effect of formulation and food on the pharmacokinetics of Indoximod in healthy volunteers. Part 1 is an open-label, 3-period, 6-sequence study. Participants will receive single doses of Indoximod base or salt formulation, in the fasted or fed state. Part 2 is a randomized single ascending dose study of indoximod salt formulation to characterize the PK profile and determine the safety and tolerability of each dose in healthy male volunteers.

Conditions

Interventions

TypeNameDescription
DRUGIndoximod base formulationSpecified dose on specified days
DRUGIndoximod HCL (salt) formulationSpecified dose on specified days
OTHERPlaceboSpecified dose on specified days

Timeline

Start date
2017-11-21
Primary completion
2018-01-25
Completion
2018-04-16
First posted
2017-12-13
Last updated
2020-05-28

Locations

1 site across 1 country: Canada

Regulatory

Source: ClinicalTrials.gov record NCT03372239. Inclusion in this directory is not an endorsement.